(NASDAQ: ALGS) Aligos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.11%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.32%.
Aligos Therapeutics's earnings in 2026 is -$90,321,000.On average, 7 Wall Street analysts forecast ALGS's earnings for 2026 to be -$41,027,918, with the lowest ALGS earnings forecast at -$43,846,035, and the highest ALGS earnings forecast at -$36,451,728. On average, 7 Wall Street analysts forecast ALGS's earnings for 2027 to be -$27,566,677, with the lowest ALGS earnings forecast at -$30,746,805, and the highest ALGS earnings forecast at -$21,962,003.
In 2028, ALGS is forecast to generate -$7,700,625 in earnings, with the lowest earnings forecast at -$23,651,388 and the highest earnings forecast at $27,809,874.